依赖股东方独家供应部件

港股IPO招股书披露先例 · 3 家公司,3 项

依赖控股股东相关方独家或有限供应关键部件,指发行人的核心部件、产品或商标主要来源于控股股东及其关联方授权或供应的情形。招股书通常于概要、风险因素、业务及与控股股东关系等章节,披露相关采购占总采购额的比重、涉及部件及供应关系的性质;申请人一般以董事认为双方关系稳定、终止供应风险甚微、独立报告显示市场存在替代供应商,或已签订长期商业供应协议、独家授权安排及赋予优先谈判权等方式作出解释。

2026-08-31Application Proof
广西玉柴船电动力股份有限公司Guangxi Yuchai Marine and Genset Power Co., Ltd.

依赖控股股东相关方供应特定部件

In particular, during the Track Record Period, GYMCL Related Parties were our limited source of suppliers for components such as cylinder block rough castings, cylinder head rough castings and cylinder blocks for certain specific engine series, and we procured substantially all such components primarily from them.

Business · 第 148 页

Our Directors are of the view that this arrangement will not affect the operations of our business because we have maintained a good and stable relationship with GYMCL Related Parties, and the risk of GYMCL Related Parties terminating the supply of such components to us is remote.

Business · 第 148 页

In addition, according to Frost & Sullivan, there are other alternative suppliers in the market which can supply comparable components in comparable quantities.

Business · 第 148 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-10Application Proof
四川好医生云医疗科技集团股份有限公司GOOD DOCTOR CLOUD HEALTHCARE & TECHNOLOGY GROUP CO., LTD.

自有品牌商标依赖控股股东独家授权

The brands we use in our private-label pharmaceutical business, such as “Shu Han Ben Cao (蜀漢本草)”, “Fu Xin (芙新)”, “Gu Fang Xuan Hu (古方懸壺)”, “Chi Ming (馳銘)” and “Hao Jian Shan (好健膳)” are owned by us or licensed exclusively to us by Sichuan JND and its subsidiaries through an exclusive licence, and typically presented side-by-side with the “Good Doctor” trademark (“ ”) owned by Sichuan JND’s subsidiary and licensed for our use.

Business · 第 134 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2025-03-13Prospectus
维升药业VISEN Pharmaceuticals02561.HK

全部管线产品授权自控股股东Ascendis Pharma

We have one Core Product and two other pipeline drug candidates, all of which were in-licensed from our collaboration partner and one of the Controlling Shareholders, Ascendis Pharma.

Summary · 第 1 页

We expect to procure the Core Product from Ascendis Pharma for the commercial supply until 2028 following our anticipated commercialization activities in late 2025 after BLA approval.

Summary · 第 7 页

The interests of Ascendis Pharma are highly aligned with ours.

Summary · 第 16 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us